Sector News

Top U.S. execs flee Ranbaxy as Sun Pharma merger looms: paper

October 13, 2014
Life sciences
Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmaceuticals is preparing to take over, the company’s top U.S. leadership is throwing in the towel.
 
According to the Indian newspaper, Business Standard, up to a half-dozen of the company’s U.S. execs are headed for the door, with country chief Venkatachalam Krishnan among them. Citing unnamed sources, the paper says department heads in finance, legal, sales and distribution have also turned in their resignations.
 
Sun Pharma agreed to buy Ranbaxy in April in a $4 billion deal and awaits regulatory approval for closing the deal. As the buyout was announced, sources started chattering that Sun would phase out the Ranbaxy brand in the U.S. Sun was also said to be planning to oust plant managers who had presided over serious manufacturing violations that landed Ranbaxy in hot water repeatedly since 2009.
 
It’s clear that Sun will have its hands full dealing with Ranbaxy’s checkered regulatory history. Four facilities are operating under a consent decree with the FDA, and the Department of Justice has issued a subpoena for information on a plant in Toansa, India, previously banned by the FDA. Sun will also have to deal with at least one state government investigation into Ranbaxy’s potential Medicaid overcharges.
 
Meanwhile, Sun has racked up its own series of recalls since announcing it would buy Ranbaxy. The company had announced three recalls by June, and an FDA warning letter chided Sun for dirty facilities, data-manipulation problems, and lax quality control, similar to the infractions that snagged Ranbaxy.
 
This wouldn’t be the first exodus from Ranbaxy in recent months. As the Business Standard points out, global quality chief Dale Adkisson and global HR head Sandeep Girotra said their goodbyes recently.
 
By Tracy Staton
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”